Undenatured Type II Collagen + Glucosamine sulfate + Boswellia serrata + Boron

• Approved Indications:
• Dietary supplement combination formulated to support joint health, improve mobility, and reduce symptoms associated with degenerative joint diseases.
• Management of osteoarthritis (mild to moderate) to relieve joint pain, stiffness, and inflammation.
• Adjunctive support in inflammatory joint conditions such as rheumatoid arthritis to help reduce immune-mediated cartilage damage and inflammation.
• Clinically Accepted Off-Label Uses:
• Use in sports medicine for joint protection in athletes.
• Support for individuals experiencing age-related joint discomfort or mild cartilage wear.
• Potential complementary therapy for autoimmune joint disorders.

• Adults:
• Typical daily doses (may vary by product formulation):
• Undenatured Type II Collagen: 40 mg once daily, orally.
• Glucosamine Sulfate: 1,000 to 1,500 mg daily, divided doses or once daily.
• Boswellia Serrata extract (standardized to 65–70% boswellic acids): 100–300 mg two to three times daily.
• Boron (as boron citrate or boron glycinate): 3–6 mg daily.
• Pediatrics:
• Safety and efficacy not established; use generally not recommended.
• Elderly:
• Same dosing as adults; dose adjustments generally not required.
• Special Populations:
• No established dose adjustments for renal or hepatic impairment; use caution.
• Route of Administration:
• Oral capsules or tablets.
• Duration:
• Benefits typically observed after 4 to 12 weeks of continuous use.
• Long-term use up to 6–12 months studied with favorable safety profile.

This multi-ingredient formulation acts through complementary mechanisms to promote joint health:

• Undenatured Type II Collagen: Induces oral immune tolerance, modulating autoimmune responses against endogenous cartilage collagen, thereby reducing inflammation and cartilage breakdown.
• Glucosamine Sulfate: Serves as a substrate for glycosaminoglycan synthesis, supporting cartilage repair and maintenance, and may exhibit mild anti-inflammatory effects.
• Boswellia Serrata: Contains boswellic acids that inhibit 5-lipoxygenase, reducing leukotriene-mediated inflammation in joints.
• Boron: Trace mineral involved in bone metabolism and inflammatory modulation; supports calcium and magnesium metabolism and may enhance joint structure integrity.

Together, these agents reduce joint inflammation, protect cartilage from degradation, and improve joint function.

• Undenatured Type II Collagen:
• Minimally absorbed intact; acts locally via induction of oral tolerance in gut immune tissue.
• Proteolytically degraded into peptides and amino acids.
• Glucosamine Sulfate:
• Well absorbed orally with bioavailability around 26%.
• Distributed to cartilage and connective tissues.
• Eliminated primarily via renal excretion; half-life approximately 15 hours.
• Boswellia Serrata:
• Boswellic acids absorbed variably; peak plasma levels within 1–3 hours.
• Metabolized in liver; excreted mainly via bile.
• Boron:
• Absorbed efficiently from the gastrointestinal tract.
• Excreted primarily via urine.
• Onset of Action:
• Clinical benefits generally require weeks to months due to cumulative effects on cartilage and inflammation.

• Pregnancy:
• No well-controlled human studies; use only if clearly necessary.
• Classified as pregnancy category N (not classified).
• Lactation:
• Limited data available; caution advised.
• Consult healthcare provider before use during breastfeeding.

• Nutritional supplement combination
• Joint health and anti-inflammatory agents

• Known hypersensitivity to any component (chicken proteins, shellfish or glucosamine sources, Boswellia, or boron).
• Severe renal or hepatic impairment without medical supervision.
• Pregnancy and lactation unless advised by a healthcare professional.

• Use caution in individuals allergic to shellfish (glucosamine source) or chicken products.
• Boswellia may cause gastrointestinal irritation; monitor for adverse symptoms.
• Boron intake should not exceed recommended doses to avoid toxicity.
• Not a replacement for prescription medications for arthritis or autoimmune diseases.
• Discontinue use if allergic reactions or severe adverse events occur.
• Monitor for any signs of liver dysfunction if combined with other hepatically metabolized drugs.

• Common:
• Mild gastrointestinal symptoms: nausea, abdominal discomfort, diarrhea, or constipation.
• Headache or dizziness (uncommon).
• Rare:
• Allergic reactions: rash, itching, swelling.
• Elevated liver enzymes (rare with Boswellia).
• Side effects are generally mild, dose-dependent, and reversible upon discontinuation.

• Boswellia:
• May potentiate effects of anticoagulants or antiplatelet drugs, increasing bleeding risk.
• Possible additive gastrointestinal irritation with NSAIDs.
• Glucosamine:
• May interact with warfarin, increasing bleeding risk; monitor INR.
• Undenatured Type II Collagen and Boron:
• No significant known drug interactions.
• Avoid concurrent use with other supplements or medications without medical advice.

• Increasing evidence supports efficacy and safety of combined supplements in mild to moderate osteoarthritis.
• Some integrative medicine guidelines recommend combination supplements for joint symptom relief.
• No formal FDA approval; marketed as dietary supplements.
• Recent safety alerts emphasize monitoring of liver function and bleeding risks when combined with anticoagulants.

• Store between 20°C and 25°C (68°F to 77°F).
• Protect from moisture, heat, and direct sunlight.
• Keep containers tightly closed and out of reach of children.
• No refrigeration or special handling required.